Fujita et al. reported that down-regulation of RPN2 significantly inhibited tumorigenicity and sensitized the tumors to cisplatin treatment, which lengthened the survival of mice with non-small-cell lung cancer [17]. The gene discussed is RPN2; the disease is non-small cell lung carcinoma.